Researchers today reported that an investigational anti-hypertensive therapy may perform better in controlling blood pressure than standard treatments for patients undergoing heart surgery, during a presentation at the American College of Cardiologys 56th Annual Scientific Session. Another study found that measuring a certain peptide can help evaluate dyspnea (shortness of breath) as heart- or lung-related in the general population. ACC.07 is the premier cardiovascular medical meeting, bringing together specialists from around the world to further breakthroughs in cardiovascular medicine.
Blood Pressure Control With Clevidipine Compared With Nitroglycerin, Sodium Nitroprusside, or Nicardipine in the Treatment of Perioperative Hypertension: Results of the Three Randomized ECLIPSE Trials (Presentation Number: 415-8)
While nitroglycerin and sodium nitroprusside have been utilized effectively in patients undergoing cardiac surgery to control blood pressure, a new therapy called clevidipine may perform even better, according to researchers at Duke University School of Medicine. Three separate studies evaluated clevidipine, a novel third-generation intravenous (IV) dihydropyridine calcium channel blocker, to measure blood pressure control against standard alternative agents.
The studies, collectively known as ECLIPSE (Evaluation of CLevidipine In the Postoperative Treatment of Hypertension Assessing Safety Events), compared clevidipine to each of three standard therapies: nitroglycerin, nitroprusside or nicardipine. The studies assessed blood pressure control by calculating the magnitude and duration of episodes when patients blood pressure went above or below predetermined acceptable ranges, based on the area under the blood-pressure-monitoring curve (AUC) that was outside the upper or lower limits of the range during surgery and for 24 hours afterwards.